Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Schizophrenic Psychoses Clear all
Terminated Not applicable Interventional Results available

Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia

NCT03648268
View directory record Official record
Conditions
Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
Interventions
repetitive Transcranial Magnetic Stimulation (rTMS)
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Quetiapine Fumarate (SEROQUEL) & Placebo in the Treatment of Acutely Ill Patients With Schizophrenia

NCT00085891
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine Fumarate
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
29
States / cities
Birmingham, Alabama • Cerritos, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2009 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Staccato Loxapine in Agitated Patients With Schizophrenia

NCT00628589
View directory record Official record
Conditions
Patients With Schizophrenia and Acute Agitation
Interventions
Inhaled loxapine 5 mg, Inhaled loxapine 10 mg, Inhaled placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 1 Interventional Results available

A Study Measuring Effect of LY2140023 (Pomaglumetad Methionil) on Electrocardiographs in Participants With Schizophrenia

NCT01606436
View directory record Official record
Conditions
Schizophrenic Disorders
Interventions
LY2140023, Placebo, Moxifloxacin
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Garden Grove, California • San Diego, California • North Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2023 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients

NCT00845026
View directory record Official record
Conditions
Schizophrenia
Interventions
LY2140023, aripiprazole, olanzapine, risperidone
Drug
Lead sponsor
Denovo Biopharma LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Escondido, California • Garden Grove, California • Washington D.C., District of Columbia + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Sep 16, 2026, 4:46 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Brain Blood Flow Changes Elicited by Oxytocin in Volunteers With and Without Schizophrenia

NCT01123317
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 18, 2019 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients

NCT00300963
View directory record Official record
Conditions
Schizophrenia
Interventions
Talnetant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
20
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2013 · Synced Sep 16, 2026, 4:46 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Sodium Butyrate For Improving Cognitive Function In Schizophrenia

NCT02654405
View directory record Official record
Conditions
Schizophrenic Disorders, Cognitive Function
Interventions
Sodium Butyrate, Placebo
Dietary Supplement · Other
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 14, 2016 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 4 Interventional

Olanzapine Versus Active Comparator in the Treatment of Depression in Patients With Schizophrenia

NCT00034801
View directory record Official record
Conditions
Depression, Schizophrenia, Schizoaffective Disorder
Interventions
olanzapine, ziprasidone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
378 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
30
States / cities
Tuscaloosa, Alabama • Little Rock, Arkansas • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Sep 16, 2026, 4:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug Dependence

NCT01037075
View directory record Official record
Conditions
Schizophrenia, Drug Abuse/Dependency
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.

NCT00488319
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorders, Psychotic Disorders, Dementia Praecox
Interventions
Paliperidone ER
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
14
States / cities
Cerritos, California • San Diego, California • Santa Ana, California + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Not applicable Interventional

Brief Hospitalization for Schizophrenia: Strategies to Improve Treatment Outcome

NCT00018837
View directory record Official record
Conditions
Schizophrenia, Schizophrenic Disorder
Interventions
Community Re-Entry Program: What is Schizophrenia
Behavioral
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2001
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 20, 2009 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Not applicable Interventional

Modafinil Augmentation Therapy for Excessive Daytime Sleepiness and Negative Symptoms in Patients With Schizophrenia

NCT00546403
View directory record Official record
Conditions
Schizophrenia
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2009 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic

NCT02128919
View directory record Official record
Conditions
Schizophrenia, Cognition, Cigarette Smoking
Interventions
tDCS
Device
Lead sponsor
Nathan Kline Institute for Psychiatric Research
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Orangeburg, New York
Source: ClinicalTrials.gov public record
Updated Aug 29, 2017 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cerebellar rTMS for the Treatment of Schizophrenic Patients

NCT01072617
View directory record Official record
Conditions
Schizophrenia
Interventions
Transcranial magnetic stimulation via MagPro x100 device
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 4 Interventional Results available

Tachyphylaxis, Tolerance, & Withdrawal Post Treatment With Igalmi for Agitation in Schizophrenia or Bipolar Disorder

NCT06041646
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia, Agitation,Psychomotor, Schizo Affective Disorder, Schizophreniform Disorders
Interventions
Sublingual film containing Igalmi
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Little Rock, Arkansas • Rogers, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind, Placebo Controlled, Multi-center and Tolerability of RBP-7000 in Schizophrenia Patients

NCT02109562
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000, Placebo, Risperidone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
32
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia

NCT00333177
View directory record Official record
Conditions
Schizophrenia
Interventions
Cognitive remediation training (CT), Healthy behavior training (HBT), Risperidone, administered orally (Oral Ris), Risperidone, administered via injection (RLAI)
Behavioral · Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 45 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 25, 2020 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Pharmacotherapy for Schizophrenic Drug Users - 6

NCT00000281
View directory record Official record
Conditions
Cocaine-Related Disorders, Substance-Related Disorders, Shcizophrenia
Interventions
Amantadine
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 1999
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 16, 2026, 4:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Brain Circuits in Schizophrenia and Smoking

NCT01369966
View directory record Official record
Conditions
Schizophrenia, Smoking Cessation, Nicotine Abuse
Interventions
Not listed
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 62 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2018 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant

NCT02658357
View directory record Official record
Conditions
Schizophrenia, Schizo-affective Disorder
Interventions
Risperidone Implant
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 60 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Iloperidone Compared With Placebo and Active Control in Subjects With Acute Schizophrenia

NCT00254202
View directory record Official record
Conditions
Schizophrenia
Interventions
Iloperidone, Ziprasidone, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
33
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 16, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Long Term Study of RBP 7000 in the Treatment of Subjects With Schizophrenia

NCT02203838
View directory record Official record
Conditions
Schizophrenia
Interventions
RBP-7000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Cerritos, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 16, 2026, 4:46 PM EDT